DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/f5c524/analytical_tool) has announced the addition of the "Analytical Tool - Lung Cancer" report to their offering.
Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2011".
According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.
This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.
Find out more about each product by clicking on respective links.
This software application is a searchable database reflects the most recent advances in the field of lung cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker's software applications give better overview, specific search capabilities and great dynamic reports.
For more information visit http://www.researchandmarkets.com/research/f5c524/analytical_tool
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
INDUSTRY KEYWORDS: Health Pharmaceutical